We also proved that venetoclax and TKIs have a synergistic effect in CML cells and this combination strategy is a practical option for targeting both BCR/ABL dependent and independent mechanisms. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.